X4 Pharmaceuticals announces EC approval of Xolremdi

X4 Pharmaceuticals (XFOR) announced that the European Commission has granted marketing authorization for Xolremdi capsules for the treatment of patients with WHIM syndrome in the European Union. “The approval of mavorixafor in the European Union marks an important step in extending access to XOLREMDI beyond the United States and providing a new, targeted therapeutic option to patients living with WHIM syndrome, an ultra-rare hematologic disorder,” said Adam Craig, executive chairman of X4 Pharmaceuticals. “We look forward to working with Norgine, our commercial partner in Europe, to enable patient access to mavorixafor to treat this devastating condition. In addition, we are now running a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenia to further explore its potential benefit across multiple diseases.”